Altium Capital Management LP Cardiff Oncology, Inc. Transaction History

Altium Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$2.11 - $7.25 $711,070 - $2.44 Million	-337,000 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$5.18 - $7.24 $61,579 - $86,069	-11,888 Reduced 3.41%	337,000 $2.03 Million
Q3 2021 Nov 15, 2021	SELL	$5.01 - $7.58 $766,479 - $1.16 Million	-152,990 Reduced 30.48%	348,888 $2.11 Million
Q2 2021 Aug 13, 2021	BUY	$6.65 - $10.04 $3.34 Million - $5.04 Million	501,878 New	501,878 $3.34 Million
Q1 2021 May 06, 2021	SELL	$9.1 - $19.57 $1.69 Million - $3.63 Million	-185,552 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$12.02 - $24.71 $2.23 Million - $4.58 Million	185,552 New	185,552 $3.34 Million

12.3M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $120M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Altium Capital Management LP with notifications on news.